Morepen Laboratories has secured a multi-year Contract Development and Manufacturing Organization (CDMO) mandate valued at approximately Rs 825 crore ($91 million) from a leading global pharma major.
Supplies under the mandate are expected to commence within the next 4–5 months, with execution scheduled through Q1 of the following financial year, subject to customary operational and regulatory processes.
This engagement marks one of the most significant single CDMO mandates in the company’s history, as it scales its global manufacturing footprint.
Built on over four decades of API manufacturing expertise and regulatory credibility, Morepen’s CDMO platform enables deeper collaboration with global pharmaceutical innovators through structured, multi-year supply programs.
The mandate reflects the Company’s growing capabilities in regulated markets, supported by internationally accredited facilities including USFDA, WHO-GMP, and EU approvals. With integrated development-to-commercial manufacturing capabilities, Morepen is positioned to support complex scale-ups and long-duration supply frameworks.
Sushil Suri, Chairman & Managing Director, Morepen Labs said “This mandate represents an important milestone in the evolution of Morepen’s manufacturing platform. It reflects the confidence global customers place in our quality systems, regulatory track record, and execution capabilities. Over the years, we have steadily strengthened our infrastructure and compliance depth, enabling participation in larger, long-duration global programmes.”
Global pharmaceutical companies are increasingly consolidating supplier networks and partnering with compliant, scalable, and reliable manufacturing platforms capable of long-term supply continuity. Morepen’s vertically integrated API capabilities, regulatory track record, and operational scale position it well to serve this evolving demand
